REGENERON AND NOVARTIS FORM STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE THE IL-1 TRAP IN RHEUMATOID ARTHRITIS AND OTHER INDICATIONS Novartis to Pay Regeneron $27 Million and Will Make $48 Million Equity Investment in Regeneron Novartis to Provide 100% Funding for Clinical Development and Provide Manufacturing Facility for Commercial Product Needs Companies Will Have Co-promotion Rights and Will Share Profits Equally
Tuesday, April 1, 2003 BiopharmaWatch Research 1 min read
Key Takeaway: REGENERON AND NOVARTIS FORM STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE THE IL-1 TRAP IN RHEUMATOID ARTHRITIS AND OTHER INDICATIONS Novartis to Pay Regeneron $27 Million and Will Make $48 Million Equity Investment in Regeneron Novartis to Provide 100% Funding for Clinical Development and Provide Manufacturing Facility for Commercial Product Needs Companies Will Have Co-promotion Rights and Will Share Profits Equally
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema
Full Press Release Details
REGENERON AND NOVARTIS FORM STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE THE IL-1 TRAP IN RHEUMATOID ARTHRITIS AND OTHER INDICATIONS Novartis to Pay Regeneron $27 Million and Will Make $48 Million Equity Investment in Regeneron Novartis to Provide 100% Funding for Clinical Development and Provide Manufacturing Facility for Commercial Product Needs Companies Will Have Co-promotion Rights and Will Share Profits Equally.